{
    "clinical_study": {
        "@rank": "154524", 
        "acronym": "SPARQ", 
        "arm_group": [
            {
                "arm_group_label": "Pitavastatin 4mg", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Atorvastatin 20mg", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "rosuvastatin 5 mg", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if Pitavastatin lowers CoQ10 less than\n      Atorvastatin or Rosuvastatin."
        }, 
        "brief_title": "A Study Comparing CoQ10 Levels While Taking 3 Different Statins", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "detailed_description": {
            "textblock": "Statins are known effectively treat high cholesterol and heart disease.  However, statins\n      may lower endogenous levels of Coenzyme10 (CoQ10).  This decrease in CoQ10 levels may be\n      responsible for side effects such as myalgia.\n\n      Previous studies have shown that Pitavastatin may not affect CoQ10 levels as other statins\n      do, while still lowering cholesterol.\n\n      In this study, investigators intend to compare the plasma levels of CoQ10 in patients taking\n      3 different FDA-approved statins, in equipotent doses."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  LDL-C levels of 100-200mg/dl; triglycerides </=200mg/dl at screening visit\n\n          -  Willing to discontinue use of all lipid-altering doses fo medication or supplements\n             for the duration of the study\n\n        Exclusion Criteria:\n\n          -  LDL-C <100mg/dl or >200mg/dl, Triglycerides >200mg/dl\n\n          -  History of diabetes mellitus or documented fasting blodo glucose >125mg/dl or HbA1c\n             >6.4%\n\n          -  History of coronary artery disease\n\n          -  history of chrinic renal or hepatic disease\n\n          -  known sensitivity of intolerance to a statin\n\n          -  persistent elevated liver enzymes or CPK (>3 x upper normal limit)\n\n          -  currently taking CoQ10 supplements and unable discontinue for duration of study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "135", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01660191", 
            "org_study_id": "12943"
        }, 
        "intervention": {
            "arm_group_label": [
                "Pitavastatin 4mg", 
                "Atorvastatin 20mg", 
                "rosuvastatin 5 mg"
            ], 
            "description": "Pitavastatin 4mg, Atorvastatin 20mg, or rosuvastatin 5mg, once daily by mouth for 12 weeks", 
            "intervention_name": "Statin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Atorvastatin", 
                "Hydroxymethylglutaryl-CoA Reductase Inhibitors", 
                "Rosuvastatin", 
                "Pitavastatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "LDL, HDL", 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kansas City", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66160"
                }, 
                "name": "University of Kansas Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Study Comparing the Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on Plasma Levels of CoQ10 (SPARQ)", 
        "overall_official": {
            "affiliation": "University of Kansas", 
            "last_name": "Patrick M Moriarty, MD, FACC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Change in levels will be measured by levels at 12 weeks minus levels at baseline", 
            "measure": "Changes in plasma CoQ10 levels", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline to 12 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01660191"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Kansas", 
            "investigator_full_name": "Patrick Moriarty, MD, FACP, FACC", 
            "investigator_title": "Director, Atherosclerosis & LDL-Apheresis Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in levels will be measured by levels at 12 weeks minus levels at baseline.  Major lipid parameters include apoA1, apoB, LDL and HDL particle number and size.", 
                "measure": "Changes in major lipid parameters", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to 12 Weeks"
            }, 
            {
                "description": "Change in levels will be measured by levels at 12 weeks minus levels at baseline.  Changes measured based in HbA1c, frusctosamine, insulin, and proinsulin.", 
                "measure": "Changes to glucose metabolism", 
                "safety_issue": "No", 
                "time_frame": "Change from Baseline to 12 weeks"
            }
        ], 
        "source": "University of Kansas", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Kowa Pharmaceuticals America, Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Eli Lilly and Company", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Kansas", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}